Section 80RRB Royalty on Patents
Section 80RRB allows a deduction of up to ₹3 lakh on royalty income received by an Indian resident patentee for a patent registered under the Patents Act 1970, subject to conditions on residency and registration.
India's patent regime benefits individual inventors through Section 80RRB, which incentivises innovation by reducing the tax burden on royalty income from patents. The deduction was introduced to align India with global practices where intellectual property income is taxed concessionally.
The deduction is available only to an individual who is both an Indian resident and the patentee — meaning the person who registered the patent or was assigned it. The patent must be registered under the Patents Act 1970. Foreign patents or patents registered overseas do not qualify for this deduction, even if the royalty is received by an Indian resident.
The maximum deduction is ₹3 lakh per year. If actual royalty income exceeds ₹3 lakh, the excess is taxable at the normal slab rate. The deduction applies to royalty income received both from Indian and foreign sources. However, where foreign royalty is involved, the deduction is restricted to the income brought into India in convertible foreign exchange within a prescribed time.
To claim the deduction, the taxpayer must furnish a certificate in Form 10CCE from a prescribed authority specifying the nature of the patent, the royalty received, and that the patent is duly registered. This is a procedural requirement frequently overlooked, and its absence during assessment can lead to disallowance of the deduction.
The section works in conjunction with India's push to develop a Patent Box regime. Countries like the UK, Netherlands, and Belgium have formal patent box regimes with substantially reduced tax rates on patent royalties; India's 80RRB is a simpler flat deduction rather than a reduced rate, but it serves a similar purpose for individual inventors.
For inventors who co-own a patent, the royalty attributed to each co-patentee's share is considered, and the ₹3 lakh ceiling applies to each individual's share. Those commercialising innovations through licensing arrangements — common in pharmaceutical and technology fields — should structure agreements to clearly identify the patent royalty component to maximise the available deduction.